TNX-650

TNX-650

TNX-650 is a medication for refractory Hodgkin's lymphoma under development by Tanox. It is currently in a phase 1 clinical trial

It is a monoclonal antibody intended to target the production of interleukin 13. [cite web |url=http://www.biospace.com/news_story.aspx?NewsEntityId=19463 |title=First Patient Dosed In Phase 1 Trial Of Tanox, Inc.'s TNX-650 - News, Search Jobs, Events |accessdate=2007-07-08 |format= |work=]

References


Wikimedia Foundation. 2010.

Игры ⚽ Нужна курсовая?

Look at other dictionaries:

  • Tanox — was a pharmaceutical company based on Houston. It was acquired by Genentech in 2007.Among the medications they have developed or are developing are: * TNX 355 * TNX 650 * TNX 901External links* http://www.tanox.com/home/home.asp …   Wikipedia

Share the article and excerpts

Direct link
… Do a right-click on the link above
and select “Copy Link”